Faculty Profiles - MORISE Masahiro

Usefulness of Transbronchial Needle Aspiration Through a Guide Sheath Using the PeriView FLEX Device in Addition to Endobronchial Ultrasonography with a Guide Sheath Transbronchial Biopsy for the Diagnosis of Pulmonary Actinomycosis Reviewed

Metabolic barriers in non-small cell lung cancer with LKB1 and/or KEAP1 mutations for immunotherapeutic strategies Reviewed International journal

Tanaka, I; Koyama, J; Itoigawa, H; Hayai, S; Morise, M

FRONTIERS IN ONCOLOGY Vol. 13 page： 1249237 2023.8

Silencing of GRHL2 induces epithelial-to-mesenchymal transition in lung cancer cell lines with different effects on proliferation and clonogenic growth Reviewed International coauthorship International journal

Kawabe, N; Matsuoka, K; Komeda, K; Muraki, N; Takaba, M; Togami, Y; Ito, Y; Yamada, M; Sunaga, N; Girard, L; Minna, JD; Cai, L; Xie, Y; Tanaka, I; Morise, M; Sato, M

ONCOLOGY LETTERS Vol. 26 ( 3 ) page： 391 2023.7

Shinohara Yuka, Ito Takayasu, Okachi Shotaro, Shimoyama Yoshie, Fukutani Eriko, Matsuzawa Reiko, Morise Masahiro, Wakahara Keiko, Ishii Makoto

The Journal of the Japan Society for Respiratory Endoscopy Vol. 45 ( 1 ) page： 37 - 42 2023.1

Language：Japanese Publishing type：Research paper (scientific journal) Publisher：The Japan Society for Respiratory Endoscopy

Background. Endobronchial ultrasonography with a guide sheath transbronchial biopsy (EBUS-GS TBB) was shown to be unsatisfactory for the diagnosis of pulmonary actinomycosis. The definitive diagnosis of pulmonary actinomycosis using EBUS-GS often necessitates penetration of the lesion to obtain samples. Case. A 52-year-old woman was referred to our hospital for the evaluation of an increase in nodules observed on chest computed tomography over 2 years prior to presentation. Results. A histopathological evaluation of specimens retrieved using EBUS-GS TBB revealed nonspecific findings, such as inflammatory cells. However, specimens retrieved via transbronchial needle aspiration through a guide sheath (GS-TBNA) using the PeriView FLEX device in addition to those obtained via EBUS-GS TBB showed necrotic tissue. Culture of tissue obtained using EBUS-GS TBB yielded Actinomyces odontolyticus. Based on these results, we diagnosed the lesion as pulmonary actinomycosis, and the patient was administered antibiotics, which led to the improvement of the lesion. Conclusion. GS-TBNA performed in addition to EBUS-GS TBB facilitated direct penetration of the lesion to obtain samples for an accurate diagnosis of pulmonary actinomycosis.

DOI： 10.18907/jjsre.45.1_37

Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade Reviewed International journal

Kobayashi, T; Iwama, S; Yamagami, A; Yasuda, Y; Okuji, T; Ito, M; Zhou, X; Ando, M; Onoue, T; Miyata, T; Sugiyama, M; Hagiwara, D; Suga, H; Banno, R; Hase, T; Morise, M; Ito, T; Kikumori, T; Inoue, M; Ando, Y; Masuda, N; Kawashima, H; Hashimoto, N; Arima, H

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM Vol. 107 ( 10 ) page： E4115 - E4123 2022.9

Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer. Reviewed International journal

Hotta K, Hida T, Nokihara H, Morise M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Yoshimoto T, Takata S, Tamura T

ESMO OPEN Vol. 7 ( 4 ) page： 100527 2022.8

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis Reviewed International journal

Gen, S; Tanaka, I; Morise, M; Koyama, J; Kodama, Y; Matsui, A; Miyazawa, A; Hase, T; Hibino, Y; Yokoyama, T; Kimura, T; Yoshida, N; Sato, M; Hashimoto, N

BMC CANCER Vol. 22 ( 1 ) page： 654 2022.6

Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE) Reviewed International journal

Hata, A; Shiraishi, Y; Inui, N; Okada, M; Morise, M; Akiyoshi, K; Takeda, M; Watanabe, Y; Sugawara, S; Shinagawa, N; Kubota, K; Saeki, T; Tamura, T

ONCOLOGY AND THERAPY Vol. 10 ( 1 ) page： 253 - 262 2022.6

Resistance to mutant KRAS V12 induced senescence in an hTERT/Cdk4-immortalized normal human bronchial epithelial cell line Reviewed International coauthorship International journal

Muraki, N; Yamada, M; Doki, H; Nakai, R; Komeda, K; Goto, D; Kawabe, N; Matsuoka, K; Matsushima, M; Kawabe, T; Tanaka, I; Morise, M; Shay, JWW; Minna, JDD; Sato, M

EXPERIMENTAL CELL RESEARCH Vol. 414 ( 1 ) page： 113053 2022.5

Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline Reviewed International journal

Iwama, S; Kobayashi, T; Yasuda, Y; Okuji, T; Ito, M; Ando, M; Zhou, X; Yamagami, A; Onoue, T; Kawaguchi, Y; Miyata, T; Sugiyama, M; Takagi, H; Hagiwara, D; Suga, H; Banno, R; Hase, T; Morise, M; Wakahara, K; Yokota, K; Kato, M; Nishio, N; Tanaka, C; Miyata, K; Ogura, A; Ito, T; Sawada, T; Shimokata, T; Niimi, K; Ohka, F; Ishigami, M; Gotoh, M; Hashimoto, N; Saito, R; Kiyoi, H; Kajiyama, H; Ando, Y; Hibi, H; Sone, M; Akiyama, M; Kodera, Y; Arima, H

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM Vol. 107 ( 4 ) page： E1620 - E1630 2022.3

INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance. Reviewed International coauthorship International journal

F Smit E, Dooms C, Raskin J, Nadal E, Tho LM, Le X, Mazieres J, S Hin H, Morise M, W Zhu V, Tan D, H Holmberg K, Ellers-Lenz B, Adrian S, Brutlach S, Schumacher KM, Karachaliou N, Wu YL

Vol. 18 ( 9 ) page： 1039 - 1054 2022.3

Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer A retrospective observational study Reviewed International journal

Oi, H; Matsuda, T; Kimura, T; Morise, M; Yamano, Y; Yokoyama, T; Kataoka, K; Kondoh, Y

MEDICINE Vol. 101 ( 6 ) page： e28863 2022.2

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations Reviewed International journal

Tanaka, I; Morise, M

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES Vol. 23 ( 1 ) 2022.1

Amelanotic Malignant Melanoma with a BRAF V600E Mutation Mimicking Primary Lung Cancer Reviewed International journal

Matsuzawa Reiko, Morise Masahiro, Tanaka Ichidai, Hayai Shunsaku, Tamiya Yutaro, Koyama Junji, Hase Tetsunari, Wakahara Keiko, Kim Deoksu, Shimoyama Yoshie, Hashimoto Naozumi

Internal Medicine Vol. 61 ( 5 ) page： 703 - 708 2022

Authorship：Corresponding author Language：English Publishing type：Research paper (scientific journal) Publisher：The Japanese Society of Internal Medicine

Amelanotic melanoma is a rare type of melanoma that shows little or no melanin pigmentation. When tumor lesions are not detected in cutaneous sites, the presence of melanin is the hallmark sign of malignant melanoma. We herein report a case of amelanotic melanoma with a BRAF V600E mutation mimicking primary lung cancer that was finally diagnosed on an autopsy. The current case suggests important caveats for the differential diagnosis of patients with BRAF V600E mutation-positive poorly differentiated lung tumors. In terms of the pathological diagnosis, routine immunohistochemical staining may be useful, especially in patients with a poorly differentiated lung tumor without TTF-1 expression.

DOI： 10.2169/internalmedicine.6657-20

Is area under the curve the best parameter for carboplatin induced emetic risk stratification? Reviewed International journal

Ozone, S; Ichikawa, K; Morise, M; Matsui, A; Kinoshita, F; Matsuzawa, R; Koyama, J; Tanaka, I; Hashimoto, N

NAGOYA JOURNAL OF MEDICAL SCIENCE Vol. 83 ( 4 ) page： 773 - 785 2021.11

Oxytocin receptor is a promising therapeutic target of malignant mesothelioma Reviewed International journal

Kodama, Y; Tanaka, I; Sato, T; Hori, K; Gen, S; Morise, M; Matsubara, D; Sato, M; Sekido, Y; Hashimoto, N

CANCER SCIENCE Vol. 112 ( 9 ) page： 3520 - 3532 2021.9

The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence Reviewed International journal

Tanaka, I; Furukawa, T; Morise, M

CANCER CELL INTERNATIONAL Vol. 21 ( 1 ) page： 454 2021.8

Tepotinib in patients with NSCLC harbouring METexon 14 skipping: Japanese subset analysis from the Phase II VISION study Reviewed International journal

Sakai, H; Morise, M; Kato, T; Matsumoto, S; Sakamoto, T; Kumagai, T; Tokito, T; Atagi, S; Kozuki, T; Tanaka, H; Chikamori, K; Shinagawa, N; Takeoka, H; Bruns, R; Straub, J; Schumacher, KM; Paik, PK

JAPANESE JOURNAL OF CLINICAL ONCOLOGY Vol. 51 ( 8 ) page： 1261 - 1268 2021.8

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study Reviewed International journal

Nakano, T; Kuribayashi, K; Kondo, M; Morise, M; Tada, Y; Hirano, K; Hayashi, M; Tanaka, M; Hirabayashi, M

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 ( 3 ) page： 264 - 272 2021.6

Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma Reviewed International journal

Nakagawa, K; Kijima, T; Okada, M; Morise, M; Kato, M; Hirano, K; Fujimoto, N; Takenoyama, M; Yokouchi, H; Ohe, Y; Hida, T; Aoe, K; Kishimoto, T; Hirokawa, M; Matsuki, H; Kaneko, Y; Yamada, T; Morimoto, C; Takeda, M

JTO CLINICAL AND RESEARCH REPORTS Vol. 2 ( 6 ) page： 100178 2021.6

Evaluation of reactivity of HISCLTM SARS-CoV-2 antibody reagent Reviewed International journal

KIKUCHI Ryosuke, SUZUKI Atsuo, KIM Jeong Hui, WATARAI Rika, MORISE Masahiro, SAITO Shoji, YAGI Tetsuya, MATSUSHITA Tadashi

Japanese Journal of Medical Technology Vol. 70 ( 2 ) page： 220 - 227 2021.4

Language：Japanese Publishing type：Research paper (scientific journal) Publisher：Japanese Association of Medical Technologists

Antibody detection reagents for the novel coronavirus SARS-CoV-2 can be classified into two types: those that detect antibodies to the spike protein S1 domain (S) and/or the nucleocapsid protein (N) of SARS-CoV-2. In this study, we evaluated the reactivity of the HISCLTM SARS-CoV-2 antibody reagent in three cases of COVID-19. In case 1, IgM antibodies were detected when using the HISCLTM SARS-CoV-2 S-IgM reagent from the time of admission to the hospital (day X). In case 2, SARS-CoV-2 antibodies were detected when using the HISCL SARS-CoV-2 S-IgM, N-IgM, and N-IgG reagents from the X + 1st day, and IgG antibodies were detected from the X + 2nd day when using the HISCLTM SARS-CoV-2 S-IgG reagent . In case 3, positive results were obtained from X + 12th day for the HISCLTM SARS-CoV-2 S-IgM and S-IgG reagents. These results suggest that among the HISCLTM SARS-CoV-2 reagents, the S-targeting antibody reagent could detect SARS-CoV-2 antibodies earlier than the N-targeting antibody reagent.

DOI： 10.14932/jamt.20-131

Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series International journal

Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations Reviewed International journal

Ninomiya, K; Teraoka, S; Zenke, Y; Kenmotsu, H; Nakamura, Y; Okuma, Y; Tamiya, A; Nosaki, K; Morise, M; Aokage, K; Oya, Y; Kozuki, T; Sakamoto, T; Tanaka, K; Tanaka, H; Tanizaki, J; Miura, S; Mizutani, H; Miyauchi, E; Yamaguchi, O; Ebi, N; Goto, Y; Sasaki, T; Daga, H; Morita, S; Yamanaka, T; Amano, S; Hasegawa, K; Imamura, CK; Suzuki, K; Nakajima, K; Nishimoto, H; Oizumi, S; Hida, T; Hotta, K; Takiguchi, Y

JTO CLINICAL AND RESEARCH REPORTS Vol. 2 ( 1 ) page： 100107 2021.1

Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET) Reviewed International journal

Takeuchi, S; Yanagitani, N; Seto, T; Hattori, Y; Ohashi, K; Morise, M; Matsumoto, S; Yoh, K; Goto, K; Nishio, M; Takahara, S; Kawakami, T; Imai, Y; Yoshimura, K; Tanimoto, A; Nishiyama, A; Murayama, T; Yano, S

TRANSLATIONAL LUNG CANCER RESEARCH Vol. 10 ( 1 ) page： 314 - 325 2021.1

Ishi Azusa, Tanaka Ichidai, Iwama Shintaro, Sakakibara Toshihiro, Mastui Toshinori, Kobayashi Tomoko, Hase Tetsunari, Morise Masahiro, Sato Mitsuo, Arima Hiroshi, Hashimoto Naozumi

Endocrine Journal Vol. 68 ( 5 ) page： 613 - 620 2021

Language：English Publishing type：Research paper (scientific journal) Publisher：The Japan Endocrine Society

The programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis is vital for immune resistance during tumor development, while PD-L1 inhibitors can also inhibit the PD-L1/B7-1 (CD80) interaction, indicating one of the molecular differences between PD-1 and PD-L1 inhibitors. However, the clinical benefits of PD-L1 inhibitors in patients previously treated with PD-1 inhibitors remain unknown. In this study, we retrospectively analyzed the clinical data of eight patients with non-small cell lung cancer who received the PD-L1 inhibitor atezolizumab and previously treated with the PD-1 inhibitor nivolumab. The median progression-free survival was 2.1 months (1.8–18.7 months), and 4 of 8 patients achieved at least stable disease. In two of these patients, atezolizumab treatment resulted in longer progression-free survival (PFS) compared with that of nivolumab. Conversely, one patient exhibited grade 4 diabetic ketoacidosis (DKA) within 2 weeks after the initial administration of atezolizumab. Another patient had developed type 1 diabetes mellitus (T1DM) during the prior nivolumab treatment and then developed DKA due to an infection after the initiation of atezolizumab. Both of them had high-risk human leukocyte antigen-DR/DQ types relevant to T1DM. These results demonstrate the potential efficacy of PD-L1 inhibitors to some tumors that have acquired resistance to PD-1 inhibitors and suggest that appropriate managements are required for not only a newly onset of T1DM but also blood glucose control after the development of T1DM during a reiteration of the PD-1/PD-L1 blockade.

DOI： 10.1507/endocrj.EJ20-0769

Comparative study of anti-SARS-CoV-2 antibody testing: Relationship between target antigen and immunoglobulin isotype Reviewed International journal

KIM Jeong Hui, KIKUCHI Ryosuke, SUZUKI Atsuo, WATARAI Rika, YOKOYAMA Satoru, MORISE Masahiro, YAGI Tetsuya, MATSUSHITA Tadashi

Japanese Journal of Medical Technology Vol. 69 ( 4 ) page： 554 - 561 2020.10

Language：Japanese Publishing type：Research paper (scientific journal) Publisher：Japanese Association of Medical Technologists

As the novel coronavirus disease (COVID-19) pandemic evolves, anti-SARS-CoV-2 antibody (Ab) testing has emerged as an additional or alternative tool for COVID-19 diagnosis. The two antigens used in serological test are the nucleocapsid protein (N) and the spike protein S1 domain (S). In this study, we aimed to validate the performance of seven types of commercial lateral flow immunoassay (LFIA) kits and four types of antibody detection reagents using autoanalyzers as serological testing for COVID-19. Seven types of LFIA kits were purchased from five companies, Kurabo, RayBiotech, Innovita Biological Technology, LumiQuick Diagnostics, and Lepu Medical Technology. Four types of antibody detection reagents were obtained from three companies, Abbot, Roche Diagnostics, and Ortho-Clinical Diagnostics. We tested sequential sera from two patients diagnosed as having COVID-19 by reverse transcription (RT)-quantitative polymerase chain reaction (qPCR). The IgG Ab against the SARS-CoV-2 N protein was detected earlier than IgM Ab, whereas IgM and IgG Ab against the SARS-CoV-2 S protein were detectable from the early stage of infection. These results suggest that S-based Ab detection has a potential for the early detection of SARS-CoV-2 in hospitals, clinics, and test laboratories.

DOI： 10.14932/jamt.20-71

Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study Reviewed International coauthorship International journal

Seto, T; Hayashi, H; Satouchi, M; Goto, Y; Niho, S; Nogami, N; Hida, T; Takahashi, T; Sakakibara-Konishi, J; Morise, M; Nagasawa, T; Suzuki, M; Ohkura, M; Fukuhara, K; Thurm, H; Peltz, G; Nishio, M

CANCER SCIENCE Vol. 111 ( 10 ) page： 3726 - 3738 2020.10

Clinical burden of immune checkpoint inhibitor-induced pneumonitis Reviewed International journal

Sakamoto, K; Fukihara, J; Morise, M; Hashimoto, N

RESPIRATORY INVESTIGATION Vol. 58 ( 5 ) page： 305 - 319 2020.9

Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer Reviewed International journal

Matsui, A; Morise, M; Tanaka, I; Ozone, S; Matsuzawa, R; Koyama, J; Hase, T; Hashimoto, N; Sato, M; Hasegawa, Y

CANCER INVESTIGATION Vol. 38 ( 7 ) page： 424 - 430 2020.8

Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation Reviewed International journal

Tanaka, I; Morise, M; Miyazawa, A; Kodama, Y; Tamiya, Y; Gen, S; Matsui, A; Hase, T; Hashimoto, N; Sato, M; Hasegawa, Y

CLINICAL LUNG CANCER Vol. 21 ( 3 ) page： 273 - + 2020.5

Reply to "Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With NoneSmall-Cell Lung Cancer Who Received Programmed Death-1 Inhibitors" Reviewed International journal

Fukihara, J; Sakamoto, K; Koyama, J; Ito, T; Iwano, S; Morise, M; Ogawa, M; Kondoh, Y; Kimura, T; Hashimoto, N; Hasegawa, Y

CLINICAL LUNG CANCER Vol. 21 ( 3 ) page： E205 - E205 2020.5

UHRF1, a Regulator of Methylation, as a Diagnostic and Prognostic Marker for Lung Cancer Reviewed International journal

Goto, D; Komeda, K; Uwatoko, N; Nakashima, M; Koike, M; Kawai, K; Kodama, Y; Miyazawa, A; Tanaka, I; Hase, T; Morise, M; Hasegawa, Y; Kawabe, T; Sato, M

CANCER INVESTIGATION Vol. 38 ( 4 ) page： 240 - 249 2020.4

Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study Reviewed International journal

Shimokawa, M; Nosaki, K; Seto, T; Ohashi, K; Morise, M; Horinouchi, H; Sakakibara, J; Murakami, H; Yano, S; Satouchi, M; Matsumoto, S; Goto, K; Yoh, K

TRIALS Vol. 21 ( 1 ) page： 298 2020.3

Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study Reviewed International journal

Okada Norio, Iwama Shintaro, Okuji Takayuki, Kobayashi Tomoko, Yasuda Yoshinori, Wada Eri, Onoue Takeshi, Goto Motomitsu, Sugiyama Mariko, Tsunekawa Taku, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Suga Hidetaka, Banno Ryoichi, Hase Tetsunari, Morise Masahiro, Kanda Mitsuro, Yokota Kenji, Hashimoto Naozumi, Ando Masahiko, Fujimoto Yasushi, Nagino Masato, Kodera Yasuhiro, Fujishiro Mitsuhiro, Hibi Hideharu, Sone Michihiko, Kiyoi Hitoshi, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

BRITISH JOURNAL OF CANCER Vol. 122 ( 6 ) page： 771 - 777 2020.3

Risk factors for pulmonary infection after diagnostic bronchoscopy in patients with lung cancer Reviewed International journal

Shimizu, T; Okachi, S; Imai, N; Hase, T; Morise, M; Hashimoto, N; Sato, M; Hasegawa, Y

NAGOYA JOURNAL OF MEDICAL SCIENCE Vol. 82 ( 1 ) page： 69 - 77 2020.2

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer Reviewed International journal

Nakagawa, K; Hida, T; Nokihara, H; Morise, M; Azuma, K; Kim, YH; Seto, T; Takiguchi, Y; Nishio, M; Yoshioka, H; Kumagai, T; Hotta, K; Watanabe, S; Goto, K; Satouchi, M; Kozuki, T; Koyama, R; Mitsudomi, T; Yamamoto, N; Asakawa, T; Hayashi, M; Hasegawa, W; Tamura, T

LUNG CANCER Vol. 139 page： 195 - 199 2020.1

Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study Reviewed International journal

Kobayashi, T; Iwama, S; Yasuda, Y; Okada, N; Okuji, T; Ito, M; Onoue, T; Goto, M; Sugiyama, M; Tsunekawa, T; Takagi, H; Hagiwara, D; Ito, Y; Suga, H; Banno, R; Yokota, K; Hase, T; Morise, M; Hashimoto, N; Ando, M; Fujimoto, Y; Hibi, H; Sone, M; Ando, Y; Akiyama, M; Hasegawa, Y; Arima, H

JOURNAL FOR IMMUNOTHERAPY OF CANCER Vol. 8 ( 2 ) 2020

Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy Reviewed International journal

Sugawara, S; Inui, N; Kanehara, M; Morise, M; Yoshimori, K; Kumagai, T; Fukui, T; Minato, K; Iwashima, A; Takeda, Y; Kubota, K; Saeki, T; Tamura, T

CANCER Vol. 125 ( 22 ) page： 4076 - 4083 2019.11

Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors Reviewed International journal

Fukihara, J; Sakamoto, K; Koyama, J; Ito, T; Iwano, S; Morise, M; Ogawa, M; Kondoh, Y; Kimura, T; Hashimoto, N; Hasegawa, Y

CLINICAL LUNG CANCER Vol. 20 ( 6 ) page： 442 - + 2019.11

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Reviewed International journal

Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N

International journal of clinical oncology Vol. 24 ( 7 ) page： 731 - 770 2019.7

Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations Reviewed International journal

Tanaka Ichidai, Morise Masahiro, Kodama Yuta, Matsui Akira, Ozawa Naoya, Ozone Sachiko, Goto Daiki, Miyazawa Ayako, Hase Tetsunari, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

LUNG CANCER Vol. 127 page： 169 - 171 2019.1

eIF2 beta, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer Reviewed International coauthorship International journal

Tanaka Ichidai, Sato Mitsuo, Kato Toshio, Goto Daiki, Kakumu Tomohiko, Miyazawa Ayako, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Sekido Yoshitaka, Girard Luc, Minna John D., Byers Lauren A., Heymach John V., Coombes Kevin R., Kondo Masashi, Hasegawa Yoshinori

CANCER SCIENCE Vol. 109 ( 6 ) page： 1843 - 1852 2018.6

Safety and efficacy of diagnostic flexible bronchoscopy in very old patients with lung cancer Reviewed International journal

Okachi Shotaro, Imaizumi Kazuyoshi, Imai Naoyuki, Shimizu Takahiro, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

EUROPEAN GERIATRIC MEDICINE Vol. 9 ( 2 ) page： 255 - 262 2018.4

Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study Reviewed International journal

Kobayashi Tomoko, Iwama Shintaro, Yasuda Yoshinori, Okada Norio, Tsunekawa Taku, Onoue Takeshi, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Morishita Yoshiaki, Goto Motomitsu, Suga Hidetaka, Banno Ryoichi, Yokota Kenji, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Ando Masahiko, Kiyoi Hitoshi, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

JOURNAL OF THE ENDOCRINE SOCIETY Vol. 2 ( 3 ) page： 241 - 251 2018.3

Prospective registry database of patients with malignant mesothelioma: directions for a future Japanese registry-based lung cancer study Reviewed International journal

Shintani Yasushi, Hasegawa Seiki, Takuwa Teruhisa, Aoe Keisuke, Kato Katsuya, Fujimoto Nobukazu, Hida Yasuhiro, Morise Masahiro, Moriya Yasumitsu, Morohoshi Takao, Okumura Meinoshin, Yoshino Ichiro

JOURNAL OF THORACIC DISEASE Vol. 10 ( 3 ) page： 1968 - 1971 2018.3

A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting Reviewed International journal

Tanaka, I; Kawada, K; Morise, M; Hase, T; Hayashi, H; Sokai, A; Fukatsu, A; Kondo, M; Nomura, F; Hasegawa, Y

CANCER CHEMOTHERAPY AND PHARMACOLOGY Vol. 81 ( 2 ) page： 339 - 345 2018.2

An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib Reviewed International journal

Sato Mitsuo, Matsui Akira, Shimoyama Yoshie, Omote Norihito, Morise Masahiro, Hase Tetsunari, Tanaka Ichidai, Suzuki Kojiro, Hasegawa Yoshinori

Internal Medicine Vol. 57 ( 23 ) page： 3429 - 3432 2018

Language：English Publishing type：Research paper (scientific journal) Publisher：The Japanese Society of Internal Medicine

Squamous cell carcinoma (SCC) transformation has been identified as a mechanism of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib or erlotinib, in EGFR-mutated lung cancer. However, whether second- or third-generation TKIs can overcome resistance due to SCC transformation remains unclear. We herein report an EGFR-mutated lung adenocarcinoma undergoing transformation into SCC that exhibited a durable response to afatinib, which is a second-generation irreversible EGFR-TKI. We suggest that afatinib can be considered as a treatment option for EGFR-mutated tumor undergoing SCC transformation, particularly in the absence of a T790M mutation.

DOI： 10.2169/internalmedicine.0999-18

Risk Factor Evaluation of Programmed Death 1 Inhibitor Related Pneumonitis in Patients with Non-Small Cell Lung Cancer Reviewed International journal

Fukihara, J; Sakamoto, K; Iwano, S; Morise, M; Hashimoto, N; Hasegawa, Y

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Vol. 197 2018

12. Clinical Practice of Lung Cancer in Elderly Patients International journal

Hasegawa Yoshinori, Morise Masahiro

Nihon Naika Gakkai Zasshi Vol. 106 ( 9 ) page： 1986 - 1990 2017.9

Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer Reviewed International coauthorship International journal

Kakumu Tomohiko, Sato Mitsuo, Goto Daiki, Kato Toshio, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Fukui Takayuki, Yokoi Kohei, Sekido Yoshitaka, Girard Luc, Minna John D., Byers Lauren A., Heymach John V., Coombes Kevin R., Kondo Masashi, Hasegawa Yoshinori

CANCER SCIENCE Vol. 108 ( 4 ) page： 732 - 743 2017.4

Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy Reviewed International journal

Omote, N; Hashimoto, N; Morise, M; Sakamoto, K; Miyazaki, S; Ando, A; Nakahara, Y; Hasegawa, Y

INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE Vol. 12 page： 3541 - 3547 2017

Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy? Reviewed International journal

Kato, T; Morise, M; Ando, M; Kojima, E; Ogasawara, T; Suzuki, R; Shindoh, J; Matsumoto, M; Sugino, Y; Ogawa, M; Nozaki, Y; Hase, T; Kondo, M; Saito, H; Hasegawa, Y

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY Vol. 142 ( 7 ) page： 1629 - 1640 2016.7

The association of intravascular stromal cells with prognosis in high-grade neuroendocrine carcinoma of the lung Reviewed International journal

Sekihara K, Hishida T, Ikemura S, Saruwatari K, Morise M, Kuwata T, Fujii S, Kojima M, Ochiai A, Funai K, Aokage K, Yoshida J, Tsuboi M, Ishii G

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY Vol. 142 ( 5 ) page： 905-912 2016.5

Drastic morphological and molecular differences between lymph node micrometastatic tumors and macrometastatic tumors of lung adenocarcinoma Reviewed International journal

Aramaki N, Ishii G, Yamada E, Morise M, Aokage K, Kojima M, Hishida T, Yoshida J, Ikeda N, Tsuboi M, Ochiai A

Vol. 142 ( 1 ) page： 37-46 2016.1

Factors Affecting the Diagnostic Yield of Transbronchial Biopsy Using Endobronchial Ultrasonography with a Guide Sheath in Peripheral Lung Cancer Reviewed International journal

Okachi Shotaro, Imai Naoyuki, Imaizumi Kazuyoshi, Iwano Shingo, Ando Masahiko, Hase Tetsunari, Aso Hiromichi, Morise Masahiro, Wakahara Keiko, Ito Satoru, Hashimoto Naozumi, Sato Mitsuo, Kondo Masashi, Hasegawa Yoshinori

Internal Medicine Vol. 55 ( 13 ) page： 1705 - 1712 2016

Language：English Publishing type：Research paper (scientific journal) Publisher：The Japanese Society of Internal Medicine

Objective Endobronchial ultrasonography with a guide sheath (EBUS-GS) and virtual bronchoscopic navigation (VBN) improves the diagnostic yield in patients with peripheral pulmonary lesions (PPLs). Most previous reports on EBUS-GS-guided transbronchial biopsy (TBB) have included patients with benign and malignant diseases. We aimed to determine the factors that predicted a successful diagnosis by EBUS-GS-guided TBB diagnostic in patients with small peripheral lung cancer, with a focus on the high-resolution computed tomography (HRCT) findings before bronchoscopy. Methods We retrospectively reviewed the medical records of 173 consecutive patients with 175 small (≤30 mm) PPLs who were diagnosed with primary lung cancer between June 2010 and October 2013 at Nagoya University Hospital. All patients underwent EBUS-GS-guided TBB with VBN using a ZioStation computer workstation (Ziosoft, Osaka, Japan). We analyzed the patient characteristics, HRCT findings, diagnostic yield, and the diagnostic factors in small peripheral lung carcinoma. Results The EBUS probe position was within the PPL in 83 of the 175 lesions (47%) and 112 (64.0%) cases were successfully diagnosed by EBUS-GS-guided TBB. A univariate analysis revealed that the following factors were associated with a significantly higher diagnostic yield: CT bronchus sign positivity, a lesion of >20 mm in diameter, a solid nodule, and a probe position that was within the lesion. The following factors were not significant: the lesion location, the number of biopsies, and the lung cancer histology. A multivariate analysis revealed that the following factors significantly affected the diagnostic yield: CT bronchus sign positivity [odds ratio (OR) =2.479]; a probe position that was within the lesion (OR=2.542); and a solid nodule (OR=2.304). Conclusion The significant factors that were significantly associated with a successful diagnosis using EBUS-GS-guided TBB in small peripheral lung carcinoma were as follows: CT bronchus sign positivity, a solid nodule, and a probe position that was within the lesion.

DOI： 10.2169/internalmedicine.55.6341